Men with ulcerative colitis may be particularly at risk for prostate cancer, according to researchers.
Men who undergo assisted reproduction have higher risk for prostate cancer, early-onset disease.
Risk higher for older age, Ashkenazi descent, genetic mutations, and personal, first-degree family history.
Prevalence of all severities of hemophilia A and hemophilia B estimated at 17.1 and 3.8 cases per 100,000.
Thirteen percent of PrEP-eligible men who have sex with men live in 30-minute-drive deserts.
Short-term cognitive behavioral therapy helpful for treating a range of internet addictions.
Risk lasts through 40 years of adulthood for underweight adolescent men.
Marijuana use also linked to worse overall semen parameters due to induction of oxidative stress.
Gynecomastia is the most common male breast disease, occurring in up to 57% of men.
11β-MNTDC is a modified testosterone with androgenic and progestational activity that is being developed as a potential male contraceptive.
A diet rich in cottonseed oil was found to improve cholesterol and triglyceride levels in healthy men.
Men who have sex with men have an increased risk of meningococcal disease, however, this risk is under-ascertained and improved surveillance is needed.
Odds of choosing screening up for men with family history, African descent, low socioeconomic status.
Men had larger reductions in metabolic syndrome Z-score, C-peptide, fat mass, heart rate.
Findings for men with intermediate- and high-risk prostate cancer
Men with higher estradiol and estradiol/testosterone levels had an increased risk for pulmonary arterial hypertension.
The USPSTF has updated its 2012 recommendations on prostate-specific antigen (PSA)-based screening for prostate cancer.
Testosterone therapy is recommended in men with hypogonadism to correct symptoms of testosterone deficiency. Men who are otherwise healthy do not need to be screened for hypogonadism.
Prostate cancer was diagnosed more frequently in men who underwent single prostate-specific antigen screening than in those who did not, but mortality was unaffected.
For men with metastatic prostate cancer, aggressive therapy has no significant advantage over conservative androgen deprivation only treatments.